BCM
ARTV

Bridgeway Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Bridgeway Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Hold
35,000
– – ﹤0.01% 1006
2025
Q4 		$150K Hold
35,000
– – ﹤0.01% 1067
2025
Q3 		$100K Hold
35,000
– – ﹤0.01% 1116
2025
Q2 		$52.9K Buy
+35,000
New +$73.5K ﹤0.01% 1133

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Bridgeway Capital Management's ARTV Position: Q1 2026 in Review

Bridgeway Capital Management held its Artiva Biotherapeutics (ARTV) position steady in Q1 2026 at 35,000 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #1006.

Bridgeway Capital Management first reported a position in ARTV in Q2 2025 and has held it in 4 quarters since. 40 funds tracked by Wall St. Rank hold ARTV as of Q1 2026.

  • Bridgeway Capital Management held 35,000 shares of Artiva Biotherapeutics worth $225K as of Q1 2026.
  • Bridgeway Capital Management left its Artiva Biotherapeutics share count unchanged in Q1 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1006 holding.
  • Bridgeway Capital Management first reported a position in Artiva Biotherapeutics in Q2 2025 and has held it in 4 quarters since.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.